WHAT IS CLAIMED IS:

1. A method of administering Factor IX to a human subject in need thereof, comprising administering to the subject a dose of at least about 25 IU/kg of a chimeric polypeptide comprising Factor IX and a FcRn binding partner (FcRn BP) at about a once weekly or longer dosing interval.

2. A method of administering Factor IX to a human subject in need thereof, comprising administering to the subject a dose of at least about 10 or at least about 20 IU/kg of a chimeric polypeptide comprising Factor IX and a FcRn binding partner (FcRn BP) at about a once weekly or longer dosing interval.

3. A method of administering Factor IX to a human subject in need thereof, comprising administering to the subject a dose of at least about 10 IU/kg of a chimeric polypeptide comprising Factor IX and XTEN at about a once weekly or longer dosing interval.

4. The method of any of claims 1-3, wherein the plasma level of said chimeric polypeptide reaches a trough of at least about 1 IU/dl after at least about 6 days in at least about 80% of a patient population or reaches a trough of at least about 1 IU/dl after at least about 6 days in said subject.

5. The method of any of claims 1-3, wherein the plasma level of said chimeric polypeptide reaches

an average trough of about 1-5 IU/dl in a patient population; or

a trough of about 1-5 IU/dl in said subject.

6. The method of any of claims 1-5, wherein less than 25% of the Factor IX chimeric polypeptide in said dose is fully phosphorylated and less than 25% of the Factor IX chimeric polypeptide in said dose is fully sulfated.

7. The method of claim 6, wherein less than about 10% of said chimeric polypeptide in said dose is phosphorylated and less than about 9% of said chimeric polypeptide in said dose is sulfated.

8. The method of any of claims 1-7, wherein said dose has a mean incremental recovery (K-Value) (activity; observed) greater than 0.75 IU/dL per IU/kg .

9. The method of claim 8, wherein said dose has a mean incremental recovery (K-Value) (activity; observed) of at least about 0.8, at least about 0.9, or at least about 1 IU/dL per IU/kg.

10. The method of any of claims 1-7, wherein said chimeric polypeptide exhibits one or more pharmacokinetic parameters, in said patient population or in said subject, selected from the group consisting of:

a mean clearance (CL) (activity) in said patient population of about 3.36 ± 0.93 mL/hour/kg;

a mean clearance (CL) (activity) in said patient population of about 3.0-3.72, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, or 3.72 mL/hour/kg;

a mean clearance (CL) (activity) in said patient population that is about 2.5 fold lower than the clearance of a polypeptide comprising said Factor IX without said FcRn BP;

a clearance (CL) (activity) in said subject of about 1.84-4.58 mL/hour/kg

a mean mean residence time (MRT) (activity) in said patient population of at least about 68.05 ± 11.16 hours;

a mean MRT (activity) in said patient population of about 60-78, 60, 62, 64, 66, 68, 70, 72, 74, 76, or 78 hours;

a mean MRT (activity) in said patent population that is about 3 fold longer than the mean MRT of a polypeptide comprising said Factor IX without said FcRn BP;

a mean residence time (MRT) (activity) in said subject of about 53.1-85.8 hours;

a mean residence time (MRT) (activity) in said subject of at least about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, or about 90 hours;

a mean $t_{1/2beta}$ (activity) in said patient population of about 52.5 ± 9.2 hours;

a mean $t_{1/2beta}$ (activity)in said patient population that is about 47-60 hours, , about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60 hours; a mean $t_{1/2beta}$ (activity) in said patient population that is about 3 fold longer than the mean $t_{1/2beta}$ of a polypeptide comprising said Factor IX without said FcRn BP;

a $t_{1/2beta}$ (activity) in said subject of about 40-67.4, about 40, about 45, about 50, about 55, about 60, about 65, about 70, or about 75, hours;

a mean incremental recovery (K value) (activity; observed) in said patient population of about 0.93 ± 0.18 IU/dL per IU/kg;

a mean incremental recovery (K value) (activity; observed) in said patient population of about 0.85-1.15, about 0.85, about 0.86, about 0.87, about 0.88, about 0.89, about 0.90, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, about 0.99, about 1.0, about 1.05, about 1.10, or about 1.15 IU/dL per IU/kg;

a mean incremental recovery (K value) (activity; observed) in said patient population that is about 24% better than the mean incremental recovery of a polypeptide comprising said Factor IX without said FcRN BP;

an incremental recovery (K value) (activity; observed) in said subject of about 0.62-1.17 IU/dL per IU/kg;

a mean Vss (activity) in said patient population of about 226 ± 67.76 mL/kg;

a mean Vss (activity) in said patient population of about 200-300, about 200, about 210, about 220, about 230, about 240, about 250, about 260, about 270, about 280, about 290, or about 300 mL/kg;

a Vss (activity) in said subject of about 145-365 mL/kg;

a mean AUC/dose (activity) in said patient population of about 32.44 ± 10.75 IU*h/dL per IU/kg;

a mean AUC/dose (activity) in said patient population of about 26-40, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, or about 40 IU*h/dL per IU/kg;

an AUC/dose in said subject of about 21.80-54.30 IU*h/dL per IU/kg.

11. The method of any of claims 1-10, wherein said dosing interval is 6-10 days.

12. The method of claim 11, wherein said dose is selected from the group consisting of about 25-110, about 30-110, about 40-110, about 50-110, about 60-110, about 70-110, about 80-110, about 90-110, and about 100-110 IU/kg.

13. The method of claim 11, wherein said dose is selected from the group consisting of, about 30-100, about 30-90, about 30-80, about 30-70, about 30-60, about 30-50, and about 30-40 IU/kg.

14. The method of claim 11, wherein said dose is selected from the group consisting of about 40-110, about 50-100, about 60-90, and about 70-80 IU/kg.

15. The method of claim 11, wherein said dose is selected from the group consisting of about 40-50, about 50-60, about 60-70, about 70-80, about 80-90, about 90-100, and about 100-110 IU/kg.

16. The method of claim 11, wherein said dose is selected from the group consisting of about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, and about 110 IU/kg.

17. The method of any of claims 11-16, wherein said dosing interval is selected from the group consisting of about 7-10, about 7-9, and about 7-8 days.

18. The method of any of claims 11-16, wherein said dosing interval is selected from the group consisting of about 8-10 and about 9-10 days.

19. The method of any of claims 11-16, wherein said dosing interval is selected from the group consisting of about 6-7 and about 8-9 days.

20. The method of any of claims 11-16, wherein said dosing interval is selected from the group consisting of about 6, about 7, about 8, about 9, and about 10 days.

21. The method of claim 11, wherein said dose is about 30-50 IU/kg and said dosing interval is about 7 days.

22. The method of any of claim 4-21, wherein said trough is reached in at least about 90% of said patient population.

23. The method of claim 22, wherein said trough is reached in about 100% of said patient population.

24. The method of any of claims 1-11, 22, and 23, wherein said dose is about 50 IU/kg, and said dosing interval is about 7 days.

25. The method of any of claims 4-11, wherein said dose is about 50 IU/kg, said dosing interval is about 7 days, and said trough is reached in about 100% of said patient population.

26. The method of any of claims 1-10, wherein said dosing interval is 9-18 days.

27. The method of claim 26, wherein said dose is selected from the group consisting of about 90-180, about 100-180, about 110-180, about 120-180, about 130-180, about 140-180, about 150-180, about 160-180, and about 170-180 IU/kg.

28. The method of claim 26, wherein said dose is selected from the group consisting of about 90-170, about 90-160, about 90-150, about 90-140, about 90-130, about 90-120, about 90-110, and about 90-100 IU/kg.

29. The method of claim 26, wherein said dose is selected from the group consisting of about 100-170, about 110-160, about 120-150, and about 130-140 IU/kg.

30. The method of claim 26, wherein said dose is selected from the group consisting of about 90-100, about 100-110, about 110-120, about 120-130, about 130-140, about 140-150, about 150-160, and about 160-170 IU/kg.

31. The method of claim 26, wherein said dose is selected from the group consisting of about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, and about 180 IU/kg.

32. The method of any of claims 26-31, wherein said dosing interval is selected from the group consisting of about 9-17, about 9-16, about 9-15, about 9-14, about 9-13, about 9-12, about 9-11, and about 9-10 days.

33. The method of any of claims 26-31, wherein said dosing interval is selected from the group consisting of about 10-18, about 11-18, about 12-18, about 13-18, about 14-18, about 15-18, about 16-18, and about 17-18 days.

34. The method of any of claims 26-31, wherein said dosing interval is selected from the group consisting of about 10-11, about 11-12, about 12-13, about 13-14, about 14-15, about 15-16, and about 16-17 days.

35. The method of any of claims 26-31, wherein said dosing interval is selected from the group consisting of about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, and about 18 days.

36. The method of claim 26, wherein said dose is about 100 IU/kg and said dosing interval is at least about 12 days.

37. The method of claim 36, wherein said trough is at least about 1 IU/dl in at least about 70%, about 80%, or about 90% of said patient population.

38. The method of claim 26, wherein said dosing interval is about 12-13 days.

39. The method of claim 26, wherein said dose is about 100 IU/kg and said dosing interval is at least about 9 days.

40. The method of claim 39, wherein the trough is at least about 1 IU/dl in about 100% of said patient population.

41. The method of claim 26 or 39, wherein said dosing interval is about 9-15 days.

42. The method of claim 26, wherein said dose is about 150 IU/kg and said dosing interval is at least about 14 days.

43. The method of claim 42, where said trough is at least about 1 IU/dl in about 100% of said patient population.

44. The method of any of claims 1-43, wherein said subject is in need of control or prevention of bleeding or bleeding episodes.

45. The method of claim 44, wherein said subject is in need of control or prevention of bleeding in minor hemorrhage, hemarthroses, superficial muscle hemorrhage, soft tissue hemorrhage, moderate hemorrhage, intramuscle or soft tissue hemorrhage with dissection, mucous membrane hemorrhage, hematuria, major hemorrhage, hemorrhage of the pharynx, hemorrhage of the retropharynx, hemorrhage of the retroperitonium, hemorrhage of the central nervous system, bruises, cuts, scrapes, joint hemorrhage, nose bleed, mouth bleed,

gum bleed, intracranial bleeding, intraperitoneal bleeding, minor spontaneous hemorrhage, bleeding after major trauma, moderate skin bruising, or spontaneous hemorrhage into joints, muscles, internal organs or the brain.

46. The method of any of claims 1-43, wherein said subject is in need of peri-operative management.

47. The method of claim 46, wherein said subject is in need of management of bleeding associated with surgery or dental extraction.

48. The method of claim 46, wherein said subject will undergo, is undergoing, or has undergone major surgery.

49. The method of claim 48, wherein said major surgery is orthopedic surgery, extensive oral surgery, urologic surgery, or hernia surgery.

50. The method of claim 49, wherein said orthopedic surgery is replacement of knee, hip, or other major joint.

51. The method of any of claims 1-43, wherein said subject is in need of prophylactic treatment.

52. The method of any of claims 1-43, wherein said subject is in need of on-demand treatment.

53. The method of claim 52, wherein said subject is in need of treatment for a bleeding episode.

54. The method of claim 53, wherein said subject is in need of treatment for hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma, trauma capitis, gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous system bleeding, bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, or bleeding in the illiopsoas sheath.

55. The method of claim 51, wherein said subject is in need of surgical prophylaxis, peri-operative management, or treatment for surgery.

56. The method of claim 53, wherein said surgery is minor surgery, major surgery, tooth extraction, tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma surgery, intracranial surgery, intra-abdominal surgery, intrathoracic surgery, or joint replacement surgery.

57. The method of any of claims 1-56, wherein said subject is human.

58. The method of any of claims 1-57, wherein said Factor IX in said chimeric polypeptide is a human Factor IX.

59. The method of any of claims 1-58, wherein said Factor IX in said chimeric polypeptide is a mutant Factor IX.

60. The method of any of claims 1-59, wherein said FcRn BP in said chimeric polypeptide is a human Fc.

61. The method of any of claims 1-60, wherein said FcRn BP in chimeric polypeptide is a mutant Fc.

62. The method of claim 58, wherein said Factor IX is at least 90% or 95% identical to a Factor IX amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 415 of SEQ ID NO:2).

63. The method of claim 62, wherein said Factor IX is identical to a Factor IX amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 415 of SEQ ID NO:2).

64. The method of claim 60, wherein said Fc is at least 90% or 95% identical to a Fc amino acid sequence shown in Table 2B without a signal sequence (amino acids 1 to 227 SEQ ID NO:4).

65. The method of claim 64, wherein said Fc is identical to a Fc amino acid sequence shown in Table 2B without a signal sequence (amino acids 1 to 227 of SEQ ID NO:4).

66. The method of any of claims 1-65, wherein said chimeric polypeptide is in the form of a hybrid comprising a second polypeptide in association with said chimeric polypeptide, wherein said second polypeptide comprises a FcRn BP.

67. The method of claim 66, wherein said chimeric polypeptide comprises a sequence at least 90% or 95% identical to the Factor IX and Fc amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 642 of SEQ ID NO:2).

68. The method of claim 67, wherein said chimeric polypeptide comprises a sequence identical to the Factor IX and Fc amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 642 of SEQ ID NO:2).

69. The method of any of claims 66-68, wherein said second polypeptide comprises a sequence at least 90% or 95% identical to the amino acid sequence shown in Table 2B without a signal sequence (amino acids 1 to 227 of SEQ ID NO:4).

70. The method of claim 69, wherein said second polypeptide comprises a sequence identical to the amino acid sequence shown in Table 2B without a signal sequence (amino acids 1 to 227 of SEQ ID NO:4).

71. The method of any of claims 1-70, wherein said patient is in need of long-term treatment at weekly or longer dosing intervals.

72. The method of any of claims 1-71, wherein said chimeric polypeptide is administered as part of a pharmaceutical composition comprising at least one excipient.

73. A polypeptide comprising a Factor IX at least 90% or 95% identical to a Factor IX amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 415 of SEQ ID NO:2), and a FcRn BP.

74. The polypeptide of claim 73, wherein said Factor IX is identical to a Factor IX amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 415 of SEQ ID NO:2).

75. A polypeptide comprising a Factor IX at least 90% or 95% identical to a Factor IX amino acid sequence shown in Table 2A with a signal sequence and propeptide and propeptide (amino acids -46 to 415 of SEQ ID NO:2), and a FcRn BP.

76. The polypeptide of claim 75, wherein said Factor IX is identical to a Factor IX amino acid sequence shown in Table 2A with a signal sequence and propeptide (amino acids -46 to 415 of SEQ ID NO:2).

77. The polypeptide of any of claims 73-65, wherein said FcRn BP is at least 90% or 95% identical to the Fc amino acid sequence shown in Table 2B (amino acids 1 to 227 of SEQ ID NO:4).

78. The polypeptide of claim 77, wherein said Fc is identical to the Fc amino acid sequence shown in Table 2B (amino acids 1 to 227of SEQ ID NO:4).

79. The polypeptide of claim 73 or 75, which comprises a sequence at least 90% or 95% identical to the Factor IX and Fc amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 642 of SEQ ID NO:2).

80. The polypeptide of claim 79, which comprises a sequence identical to the Factor IX and Fc amino acid sequence shown in Table 2A without a signal sequence and propeptide (amino acids 1 to 642 of SEQ ID NO:2).

81. The polypeptide of any of claims 73-80, which is in the form of a hybrid comprising a second polypeptide, wherein said second polypeptide comprises a FcRn BP.

82. The polypeptide of claim 81, wherein said second polypeptide comprises a sequence at least 90% or 95% identical to the amino acid sequence shown in Table 2B without a signal sequence (amino acids 1 to 227 of SEQ ID NO:4) or at least 90% or 95% identical to the amino acid sequence shown in Table 2B with a signal sequence (amino acids -20 to 227 of SEQ ID NO:4).

83. The polypeptide of claim 81, wherein said second polypeptide comprises a sequence identical to the amino acid sequence shown in Table 2B without a signal sequence

(amino acids 1 to 227 of SEQ ID NO:4) or at least 90% or 95% identical to the amino acid sequence shown in Table 2B with a signal sequence (amino acids -20 to 227 of SEQ ID NO:4).

84. The polypeptide of any of claims 73-83, which has greatly reduced phosphorylation and sulfation in comparison to plasma derived Factor IX.

85. The polypeptide of claim 84, which is less than about 10% phosphorylated and less than about 9% sulfated.

86. The polypeptide of any of claims 73-85, which has a K value greater that 0.7 or 0.75.

87. The polypeptide of claim 86, which has a K value of at least about 0.8, at least about 0.9, or at least about 1.

88. The polypeptide of any of claims 73-87, which exhibits one or more pharmacokinetic parameters, in said patient population or in said subject, selected from the group consisting of:

a mean clearance (CL) (activity) in said patient population of about 3.36 ± 0.93 mL/hour/kg;

a mean clearance (CL) (activity) in said patient population of about 3.0-3.72, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, or 3.72 mL/hour/kg;

a mean clearance (CL) (activity) in said patient population that is about 2.5 fold lower than the clearance of a polypeptide comprising said Factor IX without said FcRn BP;

a clearance (CL) (activity) in said subject of about 1.84-4.58 mL/hour/kg

a mean mean residence time (MRT) (activity) in said patient population of at least about 68.05 ± 11.16 hours;

a mean MRT (activity) in said patient population of about 60-78, 60, 62, 64, 66, 68, 70, 72, 74, 76, or 78 hours;

a mean MRT (activity) in said patent population that is about 3 fold longer than the mean MRT of a polypeptide comprising said Factor IX without said FcRn BP;

a mean residence time (MRT) (activity) in said subject of about 53.1-85.8 hours;

a mean residence time (MRT) (activity) in said subject of at least about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, or about 90 hours;

a mean $t_{1/2beta}$ (activity) in said patient population of about 52.5 ± 9.2 hours;

a mean $t_{1/2beta}$ (activity)in said patient population that is about 47-60 hours, , about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60 hours; a mean $t_{1/2beta}$ (activity) in said patient

population that is about 3 fold longer than the mean $t_{1/2beta}$ of a polypeptide comprising said Factor IX without said FcRn BP;

a $t_{1/2beta}$ (activity) in said subject of about 40-67.4, about 40, about 45, about 50, about 55, about 60, about 65, about 70, or about 75 hours;

a mean incremental recovery (K value) (activity; observed) in said patient population of about 0.93 ± 0.18 IU/dL per IU/kg;

a mean incremental recovery (K value) (activity; observed) in said patient population of about 0.85-1.15, about 0.85, about 0.86, about 0.87, about 0.88, about 0.89, about 0.90, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, about 0.99, about 1.0, about 1.05, about 1.10, or about 1.15 IU/dL per IU/kg;

a mean incremental recovery (K value) (activity; observed) in said patient population that is about 24% better than the mean incremental recovery of a polypeptide comprising said Factor IX without said FcRN BP;

an incremental recovery (K value) (activity; observed) in said subject of about 0.62-1.17 IU/dL per IU/kg;

a mean Vss (activity) in said patient population of about 226 ± 67.76 mL/kg;

a mean Vss (activity) in said patient population of about 200-300, about 200, about 210, about 220, about 230, about 240, about 250, about 260, about 270, about 280, about 290, or about 300 mL/kg;

a Vss (activity) in said subject of about 145-365 mL/kg;

a mean AUC/dose (activity) in said patient population of about 32.44 ± 10.75 IU*h/dL per IU/kg;

a mean AUC/dose (activity) in said patient population of about 26-40, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, or about 40 IU*h/dL per IU/kg;

an AUC/dose in said subject of about 21.80-54.30 IU*h/dL per IU/kg.

89. A polynucleotide encoding the polypeptide of any of claims 73-80.

90. A polynucleotide encoding the Factor IX-FcRn BP polypeptide and the second peptide of any one of claims 81-88.

91. The polynucleotide of claim 89 or 90, which is a vector, plasmid, phage, or virus.

92. The polynucleotide of any of claims 89-91, which is DNA or RNA.

93. A cultured human embryonic cell comprising the polynucleotide of any one of claims 89-92.

94. The cell of claim 93, which is a HEK293 cell.

95. A method of producing a Factor IX-FcRn BP hybrid protein comprising

culturing the cell of claim 93 or 94 under conditions that allow expression of the encoded Factor IX-FcRn BP chimeric polypeptide and the encoded polypeptide consisting essentially of FcRn BP; and

recovering the encoded Factor IX-FcRn BP hybrid protein.

96. A hybrid protein produced by the method of claim 95.

97. The hybrid protein of claim 96, which has greatly reduced phosphorylation and sulfation in comparison to plasma derived Factor IX.

98. The hybrid protein of claim 97, which is less than about 10% phosphorylated and less than about 9% sulfated.

99. The hybrid protein of any of claims 96-98, which has a K value greater that 0.7 or 0.75.

100. The hybrid protein of claim 99, which has a K value of at least about 8, about 9, or about 1.

101. The method of any of claims 66-72, wherein said chimeric polypeptide is in the form of a hybrid, wherein said hybrid consists essentially of a single chain of said chimeric polypeptide and a single chain of said second polypeptide, and wherein said chains are associated through (a) noncovalent interactions, (b) two disulfide bonds or (c) both (a) and (b).

102. The polypeptide of any of claims 81-88 and 96-100, wherein said chimeric polypeptide is in the form of a hybrid, wherein said hybrid consists essentially of a single chain of said chimeric polypeptide and a single chain of said second polypeptide, and wherein said chains are associated through (a) noncovalent interactions, (b) two disulfide bonds or (c) both (a) and (b).

103. A recombinant factor IX (rFIX) preparation, which has an incremental recovery (K-Value) in humans greater than 0.75 IU/dL per IU/kg and wherein less than 25% of the rFIX in the preparation is fully phosphorylated and sulfated.

104. The rFIX preparation of claim 103, which has an incremental recovery (K-Value) of at least about 0.8, at least about 0.9, or at least about 1 IU/dL per IU/kg.

105. The rFIX preparation of claim 103, wherein the rFIX comprises a FcRn BP.

106. The rFIX preparation of claim 105, which comprises the FcRn binding region of Fc.

107. The rFIX preparation of claim 105, which comprises the FcRn binding region of albumin.

108. The method of any of claims 1-10, wherein said dose is 10-50, 10-30, 20-50, 20-100, 10, or 20 IU/kg and said dosing interval is one time weekly.

109. The method of any of claims 1-10, wherein said dose is 15-50 or 40 IU/kg and said dosing interval is every 10 days.

110. The method of any of claims 1-10, wherein said dose is 100 IU/kg and said dosing interval is every two weeks or twice monthly.

111. The method of any of claims 1-10, wherein said dosing interval is one time weekly.

112. The method of any of claims 1-10, wherein said dose is 15-100 IU/kg and said dosing interval is 10-13 days.

113. The method of any of claims 1-10, wherein said dose 50-100 IU/kg and said dosing interval is 10-14 days, said dose is 50-150 IU/kg and said dosing interval is 14-15 days, or said dose is 100-150 IU/kg and said dosing interval is 14-16 days.

114. The method of any of claims 1-10, wherein said dose is 15-50 IU/kg and said dosing interval is 10 days, said dose is 20-70 IU/kg and said dosing interval is 11 days, said dose is 25-85 IU/kg and said dosing interval is 12 days, said dose is 30-100 IU/kg and said dosing interval is 13 days, said dose is 40-125 IU/kg and said dosing interval is 14 days, or said dose is 50–150 IU/kg and said dosing interval is 15 days.

115. The method of any of claims 1-10, which consists of a one time weekly prophylactic dosing interval.

116. The method of any of claims 1-10, which consists of a 10-14 day prophylactic dosing interval.

117. The method of any of claims 1-10, which consists of a 15-18 or 16-18 day prophylactic dosing interval.

118. The method of any of claims 1-10, which consists of a two times monthly prophylactic dosing interval.

119. The method of any of claims 1-10, which consists of a one time monthly prophylactic dosing interval.

120. The method of any of claims 1-10, which is a fixed or individualized prophylactic dose and/or dosing interval.

121. The method of any of claims 1-10, wherein said dose is administered intravenously or subcutaneously.

WHAT IS CLAIMED IS:

1. An invention not claimed in any divisional application.